CA2264020A1 - Inhibiteurs des enzymes phospholipases - Google Patents

Inhibiteurs des enzymes phospholipases Download PDF

Info

Publication number
CA2264020A1
CA2264020A1 CA002264020A CA2264020A CA2264020A1 CA 2264020 A1 CA2264020 A1 CA 2264020A1 CA 002264020 A CA002264020 A CA 002264020A CA 2264020 A CA2264020 A CA 2264020A CA 2264020 A1 CA2264020 A1 CA 2264020A1
Authority
CA
Canada
Prior art keywords
group
mmol
compound
independent
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002264020A
Other languages
English (en)
Inventor
Jean Bemis
Yibin Xiang
Neelu Kaila
John Mckew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2264020A1 publication Critical patent/CA2264020A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés ayant une formule chimique sélectionnée dans le groupe composé de (I), (II) et de (III) ou leur sel pharmaceutiquement acceptable, où: A est indépendant de tout autre groupe et a été sélectionné dans le groupe composé de -CH¿2?- et de -CH¿2?-CH¿2?-; B est indépendant de tout autre groupe et a été sélectionné dans le groupe constitué par -(CH¿2?)¿n?-, -(CH¿2?O)¿n?-, -(CH¿2?S)¿n?-, -(OCH¿2?)¿n?-, -(SCH¿2?)¿n?-, -(CH=CH)¿n?-, -(C?C)¿n?-, -CON(R¿6?)-, -N(R¿6?)CO-, -O-, -S- et -N(R¿6?)-; R¿2? est indépendant de tout autre groupe R et a été sélectionné dans le groupe constitué par -H, -COOH, COR¿5?, -CONR¿5?R¿6?, -(CH¿2?)¿n?-W-(CH¿2?)¿m?-Z-R¿5?-, -(CH¿2?)¿n?-W-R¿5?-, -Z-R¿5?-, alkyle C¿1?-C¿10?, alcényle et aryle substitué; R¿3? est indépendant de tout autre groupe R et a été sélectionné dans le groupe constitué par -H, -COOH, COR¿5?, -CONR¿5?R¿6?, -(CH¿2?)¿n?-W-(CH¿2?)¿m?-Z-R¿5?-, -(CH¿2?)¿n?-W-R¿5?-, -Z-R¿5?-, alkyle C¿1?-C¿10?, alcényle et aryle substitué. Lesdits composés inhibent l'activité des enzymes phospholipases, notamment de la phospholipase cytosolique A¿2?. L'invention décrit également des compositions pharmaceutiques comprenant lesdits composants et des méthodes de traitement les utilisant.
CA002264020A 1996-08-26 1997-08-26 Inhibiteurs des enzymes phospholipases Abandoned CA2264020A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70311596A 1996-08-26 1996-08-26
US08/703,115 1996-08-26
PCT/US1997/014943 WO1998008818A1 (fr) 1996-08-26 1997-08-26 Inhibiteurs des enzymes phospholipases

Publications (1)

Publication Number Publication Date
CA2264020A1 true CA2264020A1 (fr) 1998-03-05

Family

ID=24824076

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002264020A Abandoned CA2264020A1 (fr) 1996-08-26 1997-08-26 Inhibiteurs des enzymes phospholipases

Country Status (5)

Country Link
EP (1) EP0922028A1 (fr)
JP (1) JP2000516958A (fr)
AU (1) AU717430B2 (fr)
CA (1) CA2264020A1 (fr)
WO (1) WO1998008818A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772216B2 (en) 2001-10-22 2010-08-10 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569539B2 (en) 1996-10-30 2003-05-27 Tetra Level Holdings & Finance S.A. Gas barrier packaging laminate method for production thereof and packaging containers
AU745081B2 (en) 1997-06-27 2002-03-14 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
SK12752000A3 (sk) * 1998-02-25 2001-03-12 Genetics Institute, Inc. Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie
KR20010041343A (ko) * 1998-02-25 2001-05-15 브루스 엠. 에이센, 토마스 제이 데스로저 포스포리파제 효소의 억제제
AU3297099A (en) * 1998-02-25 1999-09-15 Genetics Institute Inc. Inhibitors of phospholipase a2
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
DE19917504A1 (de) * 1999-04-17 2000-10-19 Dresden Arzneimittel Verwendung von Hydroxyindolen, die Inhibitoren der Phosphodiesterase 4 sind, zur Therapie chronisch obstruktiver Lungenerkrankungen
JP3842043B2 (ja) 1998-04-28 2006-11-08 エルビオン アクチエンゲゼルシャフト 新規ヒドロキシインドール、ホスホジエステラーゼ４のインヒビタとしてのその使用及びその製法
DE19818964A1 (de) * 1998-04-28 1999-11-04 Dresden Arzneimittel Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
CA2336909C (fr) 1998-07-15 2009-10-20 Teijin Limited Derives de thiobenzimidazole utiles comme inhibituers de l'activite de la chymase humaine
AU7686900A (en) 1999-10-22 2001-05-08 Shionogi & Co., Ltd. Preventives or remedies for arrhythmia
US6414179B1 (en) 2000-02-18 2002-07-02 Bristol-Myers Squibb Company Alpha-and beta-substituted trifluoromethyl ketones as phospholipase inhibitors
US6492550B2 (en) 2000-02-18 2002-12-10 Bristol-Myers Squibb Company Alpha-substituted thio, -oxo trifluoromethylketones as phospholipase inhibitors
US6924391B2 (en) 2000-05-11 2005-08-02 Bristol-Myers Squibb Company Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors
US6670388B1 (en) 2000-06-27 2003-12-30 Smithkline Beecham Corporation Fatty acid synthase inhibitors
BR0112460A (pt) * 2000-07-14 2003-07-22 Lilly Co Eli Método para tratamento de sépsis
CA2415742A1 (fr) 2000-07-25 2002-01-31 Merck & Co., Inc. Indoles n-substitues utiles pour le traitement du diabete
DE10060292A1 (de) 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
IL156064A0 (en) 2000-12-28 2003-12-23 Daiichi Seiyaku Co Vla-4 inhibitors
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
ES2290318T3 (es) 2001-06-20 2008-02-16 Wyeth Derivados sustituidos de acido indolico como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1).
CA2461670A1 (fr) 2001-09-27 2003-04-10 F. Hoffmann-La Roche Ag Derives d'indole utiles comme inhibiteurs de cox ii
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7632955B2 (en) 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
TWI317634B (en) 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
JP2006504660A (ja) 2002-07-31 2006-02-09 ユーロ−セルティーク エス．エイ． アリール置換ベンゾイミダゾール類およびナトリウムチャネルブロッカーとしてのそれらの使用
US7186746B2 (en) 2002-08-29 2007-03-06 Merck & Co., Inc. Indoles having anti-diabetic activity
EP1546142A4 (fr) 2002-08-29 2007-10-17 Merck & Co Inc Indoles presentant un effet antidiabetique
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
EP1569902B1 (fr) 2002-12-10 2009-05-06 Wyeth Derives d'acide indole oxo-acetyl amino acetique substitue comme inhibiteurs d'inhibiteur-1 de l'activateur du plasminogene (pai-1)
AU2003297727A1 (en) 2002-12-10 2004-06-30 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DE60324183D1 (en) 2002-12-10 2008-11-27 Wyeth Corp Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
DK1569900T3 (da) 2002-12-10 2006-10-23 Wyeth Corp Substituerede 3-carbonyl-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7691870B2 (en) * 2003-07-11 2010-04-06 Merck Patent Gmbh Benzimidazole carboxamides as raf kinase inhibitors
US7691894B2 (en) 2003-07-24 2010-04-06 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
TW200510305A (en) * 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
WO2005113499A1 (fr) * 2004-05-20 2005-12-01 Sankyo Company, Limited Composés indoles
ZA200610357B (en) 2004-06-18 2008-02-27 Biolipox Ab Indoles useful in the treatment of inflammation
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
US7812019B2 (en) * 2004-11-24 2010-10-12 Abbott Laboratories Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
CA2593155A1 (fr) 2005-01-19 2006-07-27 Biolipox Ab Indoles utiles dans le traitement de l'inflammation
RU2007121255A (ru) 2005-01-27 2009-03-10 Вайет (Us) Способы и соединения для получения замещенных производных нафтилиндола
WO2006109633A1 (fr) * 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited Composé indole substitué
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
WO2007022321A2 (fr) 2005-08-17 2007-02-22 Wyeth Indoles substitues et procedes d'utilisation de ceux-ci
JP2009514893A (ja) 2005-11-03 2009-04-09 イリプサ， インコーポレイテッド 多価インドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
KR20090076962A (ko) 2006-11-09 2009-07-13 에프. 호프만-라 로슈 아게 인돌 및 벤조퓨란 2-카복스아마이드 유도체
AU2009296820B2 (en) 2008-09-26 2014-03-20 Merck Sharp & Dohme Llc Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8563746B2 (en) 2008-10-29 2013-10-22 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2362731B1 (fr) 2008-10-31 2016-04-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN103338767B (zh) * 2010-08-04 2018-06-22 弗吉尼亚大学专利基金会 治疗炎症性疾病的组合物和方法
EP2606031B1 (fr) 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Inhibiteurs de l'autotaxine et leurs utilisations
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
EP2797597B1 (fr) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Composés d'aldéhydes hétéroaryles substitués et leurs procédés d'utilisation dans l'accroissement de l'oxygénation tissulaire
PE20142454A1 (es) 2011-12-28 2015-02-07 Global Blood Therapeutics Inc Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
EP2890691B1 (fr) 2012-08-31 2018-04-25 Principia Biopharma Inc. Dérivés de benzimidazole en tant qu'inhibiteurs d'itk
KR20190041548A (ko) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014150258A1 (fr) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Composés et ses utilisations pour la modulation de l'hémoglobine
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (fr) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Composés aldéhydes substitués et leurs procédés d'utilisation pour accroître l'oxygénation tissulaire
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA034922B1 (ru) 2013-03-15 2020-04-07 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
EP3799872A1 (fr) 2013-11-18 2021-04-07 Forma Therapeutics, Inc. Composés tétrahydroquinoliniques pour leur utlisation en tant qu'inhibiteurs de bet
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015074081A1 (fr) 2013-11-18 2015-05-21 Bair Kenneth W Compositions de benzopipérazine en tant qu'inhibiteurs de bromodomaines bet
WO2015120133A1 (fr) 2014-02-07 2015-08-13 Global Blood Therapeutics, Inc. Polymorphes cristallins de la base libre de 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
EP4159717A1 (fr) 2014-10-06 2023-04-05 Vertex Pharmaceuticals Incorporated Modulateurs de régulateur de conductance transmembranaire de la fibrose kystique
CN104876849B (zh) * 2015-01-15 2017-05-10 昆明理工大学 一种吲哚衍生物及其用途
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
SG10201912511WA (en) 2015-12-04 2020-02-27 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
EA202192783A1 (ru) 2016-12-09 2022-02-24 Вертекс Фармасьютикалз Инкорпорейтед Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
CA3069226A1 (fr) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methodes de traitement de la fibrose kystique
EP3720849A2 (fr) 2017-12-08 2020-10-14 Vertex Pharmaceuticals Incorporated Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
EP3860975B1 (fr) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulateurs de l'hémoglobine pour le traitement de la drépanocytose
CN114478354B (zh) * 2022-02-11 2022-09-23 北京青颜博识健康管理有限公司 作为透明质酸酶抑制剂的1,3-双取代吲哚类衍生物及其在美容产品中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772216B2 (en) 2001-10-22 2010-08-10 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US8088768B2 (en) 2001-10-22 2012-01-03 The Research Foundation Of The State University Of New York Protein kinase and phosphatase inhibitors
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds

Also Published As

Publication number Publication date
AU4088297A (en) 1998-03-19
AU717430B2 (en) 2000-03-23
EP0922028A1 (fr) 1999-06-16
JP2000516958A (ja) 2000-12-19
WO1998008818A1 (fr) 1998-03-05

Similar Documents

Publication Publication Date Title
CA2264020A1 (fr) Inhibiteurs des enzymes phospholipases
CA3029202C (fr) Acides carbamoyloxymethyl triazole cyclohexyliques en tant qu'antagonistes de lpa
US6630496B1 (en) Inhibitors of phospholipase enzymes
EP1307457B1 (fr) Composes azabicycliques, leur preparation et leur utilisation comme medicaments , notamment comme anti-bacteriens
CA2322163A1 (fr) Inhibiteurs de la phospholipase a2
US5180723A (en) Certain sulfonamide heterobicyclic platelet activating factor antagonists
AU768726B2 (en) Indole derivatives and their use for the treatment of osteoporosis amongst other applications
JPS63246372A (ja) ３−ヘテロ置換−ｎ−ベンジル−インドール
BR112013010099B1 (pt) Boronatos como inibidores de arginase
JP2009522232A (ja) Ｐｄｆインヒビター
GB2207672A (en) Sulphonamidothienylcarboxylic acid compounds
EP0536163A1 (fr) Amides de pyrrolidine et de thiazolidine aromatiques
FR2674855A1 (fr) Derives de piperidine, leur preparation et leur application en therapeutique.
AU708291B2 (en) Indole derivatives as EAA antagonists
JP3118738B2 (ja) （チオ）ウレア誘導体
MX2015007279A (es) Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenergicos y como antagonistas muscarinicos m3.
US5977136A (en) Tetrahydroquinolines as NMDA antagonists
JPS6222986B2 (fr)
CA2285454A1 (fr) Composes et compositions pour traitement de maladies associees a une serine protease, en particulier une activite de tryptase
JPH06500085A (ja) ベンズイミダゾール、その製造および使用法
KR19990035780A (ko) Ｐｌａ２ 억제제로서의 에스테르 및 아미드
EP0605434B1 (fr) Derives imidazo (4,5-c) pyridiniques utilises comme antagonistes du facteur activateur des plaquettes
US5089485A (en) Anti-inflammatory furanones
JPS6019767A (ja) カルボスチリル誘導体を有効成分とする抗潰瘍剤
FI70572C (fi) Foerfarande foer framstaellning av farmaceutiskt anvaendbara pyrrolidinderivat samt vid deras framstaellning anvaendbara foereningar

Legal Events

Date Code Title Description
FZDE Discontinued